Compound guide · Tier D
BPC-157
One of the most sold research peptides in the world, and one of the least supported by human evidence. This page is short because the evidence is.
The short answer
The gap between how confidently BPC-157 is marketed and what has actually been demonstrated in humans is the widest of any compound we cover. That is the finding.
At a glance
| Class | Synthetic pentadecapeptide, a 15 amino acid sequence derived from a protein found in gastric juice |
| Developer | No commercial developer. Originating academic group in Croatia. |
| Sold as | No brand name. Not a medicine anywhere. |
| Regulatory status | Not approved by any regulator anywhere, for any indication. |
| Compounding status | Classified by the FDA as a 503A Category 2 bulk drug substance in September 2023, prohibiting its use in compounding. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend it for the 503A bulk substances list, overruling FDA staff scientists. That recommendation is non-binding and starts a rulemaking process estimated at 12 to 24 months. Nothing has changed in law yet. |
| Anti-doping | Captured by S0, which prohibits at all times any substance not approved by a government regulatory authority for human therapeutic use. No therapeutic use exemption is available. |
| Our evidence tier | Tier D. Preclinical evidence only |
What it is
BPC-157 is a synthetic 15 amino acid sequence derived from body protection compound, a protein identified in gastric juice. Preclinical work, overwhelmingly in rats, reports effects on tendon, ligament, muscle and gut tissue healing, with proposed mechanisms involving angiogenesis and growth factor pathways. The sequence does not occur as a discrete natural peptide; it is a fragment synthesised because the parent protein showed activity.
Who it is for, and who actually takes it
There is no approved indication and no approved population. No regulator has assessed it for any use.
It is bought principally by people with tendon, joint or gut complaints who have found the marketing, which is extensive, and not the evidence base, which is thin. Search interest is far below the GLP-1 compounds, at roughly a tenth of tirzepatide over the past twelve months.
What the research shows
There is no efficacy chart on this page because there is no controlled human efficacy data to chart. As of 2026 the published human literature amounts to roughly three pilot studies totalling fewer than thirty participants between them, with no randomised controlled trials. Plotting rodent results as though they answered a human question is exactly the move this site exists to refuse.
Dosing
We publish no dosing information for BPC-157 and there is none to publish. No regulator has approved a dose, no controlled human trial has established one, and the schedules circulating on vendor sites and forums are not derived from human data. Anyone presenting a BPC-157 protocol as evidence based is presenting something the literature does not contain.
What happens when you come off it
The question does not arise in any evidenced form. With no controlled human efficacy data there is no established effect to be maintained or lost, and no discontinuation study exists.
What it is being studied for
| Area | Stage of evidence |
|---|---|
| Tendon, ligament and muscle healing | Preclinical, principally rat models |
| Gastrointestinal ulceration and inflammatory bowel models | Preclinical |
| Nerve and vascular injury models | Preclinical |
| Human safety and tolerability | Small pilot studies only, fewer than 30 participants published in total |
Phase 1 work has been described as underway by the originating research group. No completed human efficacy trial had been published as of 2026.
Common myths
It is proven to heal tendons.
It is proven to do things in rats. The human efficacy literature consists of a small number of pilot studies with fewer than thirty participants in total and no randomised controlled trials. Species belongs in the sentence, and here the species is not human.
The FDA approved it in July 2026.
It did not. An advisory committee voted 8 to 6 to recommend it for the 503A bulk substances list. That recommendation is non-binding, it went against the FDA's own scientific staff, and it begins a rulemaking process expected to take one to two years. As of now BPC-157 remains a Category 2 substance prohibited in compounding.
It is natural, so it is safe.
It is a synthetic fragment. The sequence was derived from a protein found in gastric juice, but the compound sold in vials is manufactured, not extracted, and does not exist as a discrete peptide in the body. Natural origin would not establish safety in any case.
It is fine for tested athletes.
S0 of the WADA prohibited list captures any substance not approved by a government regulatory authority for human therapeutic use, at all times, with no therapeutic use exemption available. BPC-157 meets that description regardless of whether it is named individually.
Thousands of user reports count as evidence.
They are uncontrolled, unblinded and unverifiable, in a condition category where spontaneous recovery is common and placebo response is well documented. That is the exact circumstance in which anecdote is least reliable.
Verifying a purchase
Because BPC-157 has no pharmacopoeial monograph and no reference standard, identity confirmation rests entirely on mass spectrometry against the stated molecular formula. It is a short peptide, which makes it cheap to synthesise and correspondingly less attractive to counterfeit than the GLP-1s, but also means deletion sequences from incomplete synthesis are a realistic impurity. Ask for the integration table, not just a purity number.
The general method is set out in our guide to reading a certificate of analysis, which covers the eleven checks that apply to any compound. The points above are the ones specific to BPC-157.
Caveats and safety
The honest safety statement is that nobody knows. There is no controlled human safety dataset of meaningful size, no long-term data at all, and no pharmacovigilance. Absence of reported harm in a market with no reporting system is not evidence of safety. Angiogenic mechanisms of the kind proposed for BPC-157 warrant particular caution in anyone with a cancer history, and that caution is theoretical precisely because the studies that would settle it have not been done.
Where to get it
Where to get it
CertaPeptides Romania, EU. Volume discounts at 3+, 5+ and 10+ units.
| Vial | Price |
|---|---|
| 2 mg | €19.99 |
| 5 mg | €43.99 |
| 10 mg | €77.99 |
| 20 mg | €109.99 |
Stated purity. ≥98% stated batch specification. Published lot report #200860 returned 99.62% on a 20 mg vial.
Documentation. Selected lots independently tested by Janoshik Analytical (Czech Republic), HPLC plus mass spectrometry, reports searchable on the Janoshik public portal and at certapeptides.com/verify.
BPC-157 is sold as laboratory research material. The vendor states it is not for human consumption and that it is not approved by the FDA, the EMA or any other regulator for use in humans or animals. Read the evidence tier at the top of this page before the price.
View BPC-157 at CertaPeptidesAffiliate link. We earn a commission if you buy, at no extra cost to you. It does not change a word of the assessment above. Every product we have priced, in one list.
Sources
- Multifunctionality and possible medical application of the BPC 157 peptide, literature and patent review
- FDA 503A bulk drug substances categories
- WADA prohibited list, S0 unapproved substances
Related compounds
Disclosure. PeptoPurity is an affiliate of CertaPeptides and earns a commission on qualifying purchases made through the vendor link on this page, at no additional cost to you. That relationship does not set the evidence tier, alter the verdict, or change a word of the assessment. Our Tier C and Tier D pages carry the same links as our Tier A pages, with the same conclusions we would publish if we earned nothing. Where the registered, prescribed route is the better option, we say so on the page that would otherwise pay us.
Scope. This is an evidence review, not medical advice. Where an approved label schedule is reproduced it is a record of what a regulator has published about a licensed medicine, not a recommendation and not a schedule for anyone to follow unsupervised. For unapproved compounds we report only the doses used in published studies, attributed to those studies, and we publish no protocols and no reconstitution guidance for any compound. Regulatory status differs between countries and changes over time. Material sold for laboratory research is not approved for human use. Decisions about treatment belong with a qualified prescriber.